Xeljanz xr and C-reactive protein increased - a phase IV clinical study of FDA data

Summary:

C-reactive protein increased is reported as a side effect among people who take Xeljanz xr (tofacitinib citrate), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Enbrel, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have C-reactive protein increased when taking Xeljanz xr. It is created by eHealthMe based on reports of 106,412 people who have side effects when taking Xeljanz xr from the FDA, and is updated regularly.

What is Xeljanz xr?

Xeljanz xr has active ingredients of tofacitinib citrate. eHealthMe is studying from 106,446 Xeljanz xr users. Check the latest studies of Xeljanz xr.

What is C-reactive protein increased?

C-reactive protein increased is found to be associated with 1,566 drugs and 2,281 conditions by eHealthMe. Check the latest studies of C-reactive protein increased.

On Jul, 19, 2026

106,412 people reported to have side effects when taking Xeljanz xr.
Among them, 325 people (0.31%) have C-reactive protein increased.

Could Xeljanz xr cause C-reactive protein increased?

Among these 325 people:

How long have people been on Xeljanz xr when they have C-reactive protein increased? *

Click here to view more results

What is the gender of people who have C-reactive protein increased when taking Xeljanz xr? *

Click here to view

What is the age of people who have C-reactive protein increased when taking Xeljanz xr? *

Click here to view more results

* Approximation only. Some reports may have incomplete information.

Do you take Xeljanz xr and have C-reactive protein increased?

- Check whether C-reactive protein increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Xeljanz xr:

Xeljanz xr (106,446 reports)

C-reactive protein increased treatments and more:

C-reactive protein increased (52,373 reports)

How severe was C-reactive protein increased and when was it recovered:

C-reactive protein increased in Xeljanz xr

Expand to all the drugs that have ingredients of tofacitinib citrate:

C-reactive protein increased and drugs with ingredients of tofacitinib citrate (4,352 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Xeljanz xr:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with C-reactive protein increased:

C-reactive protein increased (1,566 drugs)

Browse all the conditions that are associated with C-reactive protein increased:

C-reactive protein increased (2,281 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tofacitinib citrate (the active ingredients of Xeljanz xr) and Xeljanz xr (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.